Kura Oncology Inc. (NASDAQ:KURA)’s share price traded down 5.1% on Wednesday . The stock traded as low as $5.20 and last traded at $5.21, with a volume of 130,494 shares. The stock had previously closed at $5.49.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research upgraded shares of Kura Oncology from a “sell” rating to a “hold” rating in a research note on Tuesday. Oppenheimer Holdings Inc. reiterated an “outperform” rating and issued a $16.00 price objective on shares of Kura Oncology in a research note on Sunday, August 14th.

The stock has a 50 day moving average of $4.33 and a 200-day moving average of $3.68. The stock’s market capitalization is $98.03 million.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by $0.02. On average, equities research analysts predict that Kura Oncology Inc. will post ($1.58) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.